| IPO Company Profile © ipodata.com |
| Message Board | SEC Filings | Peer IPO Companies |
| Signal Pharmaceuticals, Inc. |
| 5555 Oberlin Drive, San Diego, CA 92121 * (858) 558-7500 |
| Business Description | The company is a biopharmaceutical company focused on discovering, developing and commercializing new classes of small molecule drugs that regulate genes associated with disease. |
|
Filing Information Not yet | |||
| To Trade As | SGNL (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 2/18/00 |
| Domestic Shares Filed | 5,000,000 | Filing Range | $13.00 - $15.00 |
| Foreign Shares Filed | 0 | Offering Amount | $70,000,000 |
| Company Shares | 5,000,000 | Est. Expenses | - - |
| Selling Shrhldrs Shares | 0 | Post-IPO Shares | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Robertson, Stephens & Company | Lead Manager | (415) 989-8500 |
| Chase H&Q; | Co-manager | (415) 439-3626 |
| CIBC World Markets | Co-manager | (212) 667-7400 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | - - Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/97 | 12/31/98 | 12/31/99 | ||||
| Revenues | - | - | 7.580 | 15.414 | 11.748 | - | - |
| Income from Oper. | - | - | -5.549 | -4.957 | -8.010 | - | - |
| Net Income | - | - | -5.740 | -4.356 | -7.856 | - | - |
| E.P.S | - | - | -5.650 | -3.310 | -4.790 | - | - |
| Revenue Growth (%) | - | - | 103.36 | -23.783 | - | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -2.88 | - | - | ||||
| Cash Flow - Inv. | 3.51 | - | - | ||||
| Cash Flow - Fin. | -0.51 | - | - | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 12/31/99 | Financial Ratios | ||||
| Total Assets | 14.54 | Current Assets | 14.54 | Current Ratio | 2.42 |
| Total Liab. | 8.56 | Current Liab. | 6.00 | Debt Ratio | 58.85% |
| Total Equity | 5.98 | Working Cap. | 8.54 | Debt to Equity Ratio | 1.43 |
| Cash | 6.61 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development, the acquisition of research and development technologies, compound libraries and product rights, capital investments, repayment of debt and working capital and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Brobeck, Phleger & Harrison |
| Registrar/Transfer Agent | ChaseMellon Shareholder Services, L.L.C. |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |
| Industry Competition |
. |
| Principal Shareholders | ||
| Name of Shareholder | % Owned Before | % Owned After |
| Ares-Serono S.A. | 13.10 | |
| Venrock Associates | 10.60 | |
| Accel Partners | 10.40 | |
| Kleiner Perkins Caufield & Byers | 10.00 | |
| InterWest Partners | 8.00 | |
| Lombard Odier & Cie | 5.60 | |
| U.S. Venture Partners | 5.20 | |
| Oxford Bioscience Partners | 5.20 | |
| Note: represents ownership of 5% or more prior to the offering. | ||